CN108997451B - 野八角新倍半萜及其制备方法、应用和药物组合物 - Google Patents
野八角新倍半萜及其制备方法、应用和药物组合物 Download PDFInfo
- Publication number
- CN108997451B CN108997451B CN201810808497.8A CN201810808497A CN108997451B CN 108997451 B CN108997451 B CN 108997451B CN 201810808497 A CN201810808497 A CN 201810808497A CN 108997451 B CN108997451 B CN 108997451B
- Authority
- CN
- China
- Prior art keywords
- methanol
- compound
- preparation
- illicium
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930004725 sesquiterpene Natural products 0.000 title claims abstract description 19
- 150000004354 sesquiterpene derivatives Chemical class 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 244000182644 licorice root Species 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 208000006011 Stroke Diseases 0.000 claims abstract description 17
- 230000000324 neuroprotective effect Effects 0.000 claims abstract description 10
- 241000929011 Illicium simonsii Species 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 18
- 241000720991 Illicium Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 11
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
- 230000003959 neuroinflammation Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
- 239000005909 Kieselgur Substances 0.000 claims description 3
- 206010027439 Metal poisoning Diseases 0.000 claims description 3
- 208000005374 Poisoning Diseases 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 208000010501 heavy metal poisoning Diseases 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 239000002581 neurotoxin Substances 0.000 claims description 3
- 231100000572 poisoning Toxicity 0.000 claims description 3
- 230000000607 poisoning effect Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 abstract description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 12
- 230000002490 cerebral effect Effects 0.000 abstract description 12
- 235000013922 glutamic acid Nutrition 0.000 abstract description 12
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 210000002243 primary neuron Anatomy 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 239000004090 neuroprotective agent Substances 0.000 abstract 1
- 238000013417 toxicology model Methods 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 14
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical group O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 210000003618 cortical neuron Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 9
- 229950009041 edaravone Drugs 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000019581 neuron apoptotic process Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- -1 sesquiterpene compound Chemical class 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000009223 neuronal apoptosis Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000320 anti-stroke effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域
本发明涉及化合物提取分离领域,特别涉及野八角新倍半萜及其制备方法、应用和药物组合物。
背景技术
野八角(IliiciumsimonsiiMaxim)为八角属(Illicium L.)植物,产于我国贵州西北部至西南部、四川和云南以及印度、缅甸。叶、果实入药,味辛,性热;有镇呕、行气止痛、生肌接骨、灭虱杀虫之效,可治胃寒作呕、膀胱疝气、胸前胀痛、疥疮等功效。
脑卒中(cerebral apoplexy)是导致全球人类致残的首要病因,全球第二大死因。在一些国家和城市,卒中甚至已经超过心血管病,成为第一位死因。根据中国生物技术发展中心抽样调查的数据显示,中国城乡脑血管病的年发病率平均为200/10万,患病率为400~700/10万,全国每年新发脑血管病病例250 万,死亡率为130/10万,是我国人口总死亡第二位原因,在北京已经超过心血管疾病和肿瘤,成为第一位死亡原因。全国每年用于治疗脑血管病的费用达100亿元以上,加上间接经济损失超过200亿元。由此可见,脑血管病已经成为严重影响我国民生的重要公共卫生问题。2010年世界卒中日发布的主题是“六分之一”,即全世界每6个人中有1人可能在一生中罹患卒中;每6s就有1人死于卒中;而每6min就有1人因卒中而永久致残。脑卒中是当今世界重大疾病之一。来源于中草药的有效成分是抗脑卒中新药的研究热点。
发明内容
野八角乙醇提取物具有神经保护作用,从有效部位中分离得到1个新倍半萜,药效学评价显示其具有很好的神经保护的作用。
本发明解决的技术问题在于提供了一个野八角新倍半萜;
本发明解决的另一技术问题在于提供了一个野八角新倍半萜的制备方法;
本发明解决的又一技术问题在于提供一种药物组合物,其含有一个野八角新倍半萜;
本发明解决的技术问题在于提供一种药物组合物,其含有一个野八角新倍半萜作为神经保护药物的应用。
本发明是通过以下技术方案实现的: 野八角新倍半萜具有式Ⅰ所示结构
式Ⅰ。
如式Ⅰ所示化合物的制备方法,其中,每制备15 mg式Ⅰ化合物包括以下步骤:
a.干燥的野八角果实10.50 kg,粉碎,用95% EtOH 80 L浸泡2 h后,加热回流提取3次,每次2小时,提取液减压浓缩,得到261.2 g浸膏;
b.将浸膏溶解于甲醇中,吸附于500 g硅藻土,干燥,装入索氏提取器,依次用石油醚、乙酸乙酯和甲醇索氏回流提取;
c.各提取液分别减压浓缩得石油醚部位44.2 g,乙酸乙酯部位75.0 g和甲醇部位133.6 g;
d.取甲醇洗脱部位用水溶解,吸附于10倍量的大孔吸附树脂24 h;
分别用纯水,50%乙醇:水,95%乙醇:水洗脱,得到50 %乙醇:水洗脱部位40 g,将该部位用二氯甲烷-甲醇洗脱,二氯甲烷:甲醇= 50:1;25:1;10:1;5:1;2:1;1:1;0:100,梯度洗脱分离得到流份Fr1-Fr8;
e.对7 g ,Fr 6 通过中压柱色谱法,10–60 % 的甲醇梯度洗脱,分为35个流份每500 mL为1份,通过制备液相从Fr.2-1得到权利要求1所述的野八角新倍半萜类化合物15mg。
式Ⅰ化合物在制备预防或治疗脑血管疾病药物中的应用;所述脑血管疾病药物为神经保护药物;所述脑血管疾病为脑卒中、痴呆、神经炎症、重金属中毒、神经毒剂中毒;所述脑卒中为缺血性脑卒中或出血性脑卒中。
一种药物组合物,其中,含有式Ⅰ所示的化合物以及药效学上可接受的载体。
根据本发明的思路,对野八角新倍半萜进行了神经保护相关的药理实验。氧化应激是导致神经元凋亡丢失的重要原因,是缺血性脑卒中的特征。引起氧化应激的原因有很多种,如脑缺血,神经炎症,兴奋性递质释放重摄取机制障碍,重金属暴露,神经毒性剂暴露等,表现为细胞内自由基增加,引起脂质过氧化,线粒体功能障碍继而激活凋亡通路等。谷氨酸,H2O2虽然引发神经元凋亡丢失的机制不一,但都是近年来许多国内外学者倡导的神经元损伤模型的诱发剂。研究认为,脑内兴奋性递质谷氨酸过量通常引起神经元膜上NMDA受体过度激活,从而导致神经元发生氧化应激并丢失,而H2O2是一种过氧化物,以其诱导神经细胞氧化应激损伤模型为基础,揭示了临床有效的药物作用机制,可作为体外筛选抗氧化药物的一种可靠的药理细胞模型,其发生机制,病理生理改变与脑卒中患者脑内表现具有相似性。应用谷氨酸,H2O2制作神经元损伤模型条件要求低,技术易于掌握,可靠性强,重复性好,因此在本研究中,H2O2损伤原代神经元模型、谷氨酸诱导原代神经元凋亡模型2个体外模型作为评价手段。
发明人发现新倍半萜在体外谷氨酸,H2O2诱发的大鼠大脑皮层神经元死亡的试验中均显示出优良的神经保护作用。
阳性对照药物为依达拉奉(edaravone),依达拉奉是以自由基清除为主要作用机制的神经保护药物,能有效抑制因脑缺血导致的脑细胞、血管内皮细胞、神经细胞的氧化应激损伤。
对H2O2诱发大鼠大脑皮层神经元凋亡的保护作用体外研究中,将本发明化合物与依达拉奉(300μM)用神经元培养基稀释,和大鼠大脑皮层神经元温孵24小时后,MTT法测定细胞存活率,同时进行正常对照组和阳性对照组试验。实验结果表明,正常对照组加入H2O2后570 nm处吸光度值(OD570)明显降低,阳性对照组和本发明化合物OD570明显回升,与依达拉奉(edaravone)的细胞存活率相当,新化合物组的细胞存活率与依达拉奉组相当。
对谷氨酸诱发大鼠大脑皮层神经元凋亡的保护作用体外研究中,将本发明化合物与谷氨酸(20 mM)用完全培养基稀释,和大鼠大脑皮层神经元温孵24小时后,MTT法测定细胞存活率,同时进行正常对照组和阳性对照组试验。实验结果表明,正常对照组加入谷氨酸后570 nm处吸光度值(OD570)明显降低,阳性对照组和本发明化合物OD570明显回升,与依达拉奉(edaravone)的细胞存活率相当,新化合物组的细胞存活率与依达拉奉组相当。
因此本发明的有益效果:化合物可用于制备预防和/ 或治疗脑血管疾病的药物。优选的神经退行性疾病选自脑卒中、痴呆、神经炎症、重金属中毒、神经毒剂中毒。优选的脑卒中选缺血性脑卒中和出血性脑卒中。
附图说明
图1 野八角果实的提取流程图。
具体实施方式
下面的实施例及药理活性实验进一步说明本发明,但并不意味着对本发明的任何限制。
提取分离实验(见附图1)
干燥的野八角果实10.50 kg,粉碎,用95% EtOH 80 L浸泡2 h后,加热回流提取3次,每次2小时,提取液减压浓缩,得到261.2 g浸膏。将浸膏溶解于甲醇中,吸附于500 g硅藻土,干燥,装入索氏提取器,依次用石油醚、乙酸乙酯和甲醇索氏回流提取。各提取液分别减压浓缩得石油醚部位44.2 g,乙酸乙酯部位75.0 g和甲醇部位133.6 g。取甲醇洗脱部位用水溶解,吸附于10倍量的大孔吸附树脂(24 h)。分别用纯水,50%乙醇:水,95%乙醇:水。得到50 %乙醇:水洗脱部位40 g,将该部位用二氯甲烷-甲醇(二氯甲烷:甲醇= 50:1;25:1;10:1;5:1;2:1;1:1;0:100)梯度洗脱分离得到流份Fr1-Fr8。对Fr 6 (7 g) 通过中压柱色谱法(10–60 % 的甲醇梯度洗脱)分为35个流份(500 ml为1份),通过制备液相从Fr.2-1得到一个新倍半萜类化合物(15 mg)。
新倍半萜的理化、波谱数据如下:
白色粉末; [α]20 D +15.7 (c 0.61 MeOH); IR光谱给出羟基 (3397 cm-1),羰基(1717 cm-1)等官能团的振动吸收; ESIMS m/z429 [M + H]+, 451 [M + Na]+; HRESIMSm/z451.1935 [M+ H]+ (calcd for C21H33O9, 431.1939)。见下表
表 11H and 13C NMR data of compound 1 in CD3OD
药理实验
试验材料1、受试药:本发明单体化合物。2、阳性对照药:依达拉奉,由中国食品药品检定研究院提供。HPLC检测纯度>98%。3、细胞:出生当天大鼠大脑皮层神经元。4、培养基:DMEM,FBS,美国Gibco公司生产;ES,美国Hyclone公司生产。5、H2O2由和谷氨酸由北京化工厂提供。
本发明还涉及以本发明化合物作为活性成分的药物组合物。该药物组合物可根据本领域公知的方法制备。可通过将本发明化合物与一种或多种药学上可接受的固体或液体赋形剂和/或辅剂结合,制成适于人或动物使用的任何剂型。本发明化合物在其药物组合物中的含量通常为0.1-95重量%。
本发明的化合物或含有它的药物组合物可以单位剂量形式给药,给药途径可为肠道或非肠道,如口服、鼻腔、口腔粘膜、皮肤、腹膜、直肠等。
给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂(包括真溶液和胶体溶液)、乳剂(包括o/w 型、w/o 型和复乳)、混悬剂、注射剂(包括水针剂、粉针剂和输液)、滴眼剂、滴鼻剂、洗剂和搽剂等;固体剂型可以是片剂(包括普通片、肠溶片、含片、分散片、咀嚼片、泡腾片、口腔崩解片)、胶囊剂( 包括硬胶囊、软胶囊、肠溶胶囊)、颗粒剂、散剂、微丸、滴丸、栓剂、膜剂、贴片、气(粉) 雾剂、喷雾剂等;半固体剂型可以是软膏剂、凝胶剂、糊剂等。
本发明的化合物可以制成普通制剂、也可以是缓释制剂、控释制剂、靶向制剂及各种微粒给药系统。
为了将本发明化合物制成片剂,可以广泛使用本领域公知的各种赋形剂,包括稀释剂、黏合剂、润湿剂、崩解剂、润滑剂、助流剂。稀释剂可以是淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素、硫酸钙、磷酸氢钙、碳酸钙等;湿润剂可以是水、乙醇、异丙醇等;粘合剂可以是淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、微晶纤维素、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯吡咯烷酮、聚乙二醇等;崩解剂可以是干淀粉、微晶纤维素、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、羧甲基淀粉钠、碳酸氢钠与枸橼酸、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基磺酸钠等;润滑剂和助流剂可以是滑石粉、二氧化硅、硬脂酸盐、酒石酸、液体石蜡、聚乙二醇等。
还可以将片剂进一步制成包衣片,例如糖包衣片、薄膜包衣片、肠溶包衣片,或双层片和多层片。
为了将给药单元制成胶囊剂,可以将有效成分本发明化合物与稀释剂、助流剂混合,将混合物直接置于硬胶囊或软胶囊中。也可将有效成分本发明化合物先与稀释剂、黏合剂、崩解剂制成颗粒或微丸,再置于硬胶囊或软胶囊中。用于制备本发明化合物片剂的各稀释剂、黏合剂、润湿剂、崩解剂、助流剂品种也可用于制备本发明化合物的胶囊剂。
为将本发明化合物制成注射剂,可以用水、乙醇、异丙醇、丙二醇或它们的混合物作溶剂并加入适量本领域常用的增溶剂、助溶剂、pH 调剂剂、渗透压调节剂。增溶剂或助溶剂可以是泊洛沙姆、卵磷脂、羟丙基-β-环糊精等;pH 调剂剂可以是磷酸盐、醋酸盐、盐酸、氢氧化钠等;渗透压调节剂可以是氯化钠、甘露醇、葡萄糖、磷酸盐、醋酸盐等。如制备冻干粉针剂,还可加入甘露醇、葡萄糖等作为支撑剂。
此外,如需要,也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂或其它添加剂。
为达到用药目的,增强治疗效果,本发明的药物或药物组合物可用任何公知的给药方法给药。
本发明化合物药物组合物的给药剂量依照所要预防或治疗疾病的性质和严重程度,患者或动物的个体情况,给药途径和剂型等可以有大范围的变化。一般来讲,本发明化合物的每天的合适剂量范围为0.001-150mg/Kg 体重,优选为0.1-100mg/Kg 体重,更优选为1-60mg/Kg 体重,最优选为2-30mg/Kg 体重。上述剂量可以一个剂量单位或分成几个剂量单位给药,这取决于医生的临床经验以及包括运用其它治疗手段的给药方案。
本发明的化合物或组合物可单独服用,或与其他治疗药物或对症药物合并使用。当本发明的化合物与其它治疗药物存在协同作用时,应根据实际情况调整它的剂量。
实施例1:本发明化合物对大鼠大脑皮层神经元存活状态的影响以及在H2O2诱发的神经元凋亡模型中的保护作用。
化合物对神经元存活状态的影响研究中,将原代培养大鼠皮层神经元 (DIV-9)分为对照组和给药组 (10 μM),n=6;在化合物对H2O2诱发神经元凋亡模型的保护作用研究中,将原代培养大鼠皮层神经元 (DIV-7)分为对照组,H2O2 (300μM)造模组,H2O2 (300μM)+依达拉奉 (100 μM)给药组,H2O2 (300μM)+化合物 (10μM)给药组,n=6。给药后,细胞置于细胞孵箱中继续培养24小时,MTT法 (570nm)测定细胞存活率。以对照组吸光度为标准,计算各组吸光度与对照组的比值。
实施例2:化合物在谷氨酸诱发的大鼠皮层神经元凋亡模型中的保护作用
将原代培养大鼠皮层神经元 (DIV-9)分为对照组,谷氨酸 (20 mM)造模组,谷氨酸 (20 mM)+依达拉奉 (100 μM)给药组,谷氨酸 (20 mM)+化合物 (10 μM)给药组,n=6,于细胞孵箱中继续培养24小时后,MTT法测定细胞存活率。以对照组吸光度为标准,计算各组吸光度与对照组的比值。
表2化合物对大鼠皮层神经元存活状态的影响
表3新化合物在H2O2和谷氨酸诱导的原代神经元细胞损伤模型中的神经保护作用
注:* p<0.05 vs mod,** p<0.01 vs mod,*** p<0.001vs mod,## P < 0.01vscontrol.
实验结果表明:对已经鉴定的化合物进了初步的细胞模型筛选,化合物1体现了神经保护活性,即在谷氨酸损伤原代神经元模型中具有良好的神经保护活性,其活性与阳性药依达拉奉相当。
Claims (7)
2.如权利要求1所述化合物的制备方法,其特征在于:每制备15 mg式Ⅰ化合物包括以下步骤:
a.干燥的野八角果实10.50 kg,粉碎,用95% EtOH 80 L浸泡2 h后,加热回流提取3次,每次2小时,提取液减压浓缩,得到261.2 g浸膏;
b.将浸膏溶解于甲醇中,吸附于500 g硅藻土,干燥,装入索氏提取器,依次用石油醚、乙酸乙酯和甲醇索氏回流提取;
c.各提取液分别减压浓缩得石油醚部位44.2 g,乙酸乙酯部位75.0 g和甲醇部位133.6 g;
d.取甲醇洗脱部位用水溶解,吸附于10倍量的大孔吸附树脂24 h;
分别用纯水,50%乙醇:水,95%乙醇:水洗脱,得到50 %乙醇:水洗脱部位40 g,将该部位用二氯甲烷-甲醇洗脱,二氯甲烷:甲醇= 50:1;25:1;10:1;5:1;2:1;1:1;0:100,梯度洗脱分离得到流份Fr1-Fr8;
e.对7 g ,Fr 6 通过中压柱色谱法,10–60 % 的甲醇梯度洗脱,分为35个流份每500mL为1份,通过制备液相从Fr.2-1得到权利要求1所述的野八角新倍半萜类化合物15 mg。
3.如权利要求1所述的化合物在制备预防或治疗脑血管疾病药物中的应用。
4.根据权利要求3 所述的应用,其特征为所述脑血管疾病药物为神经保护药物。
5.根据权利要求3 所述的应用,其特征为所述脑血管疾病为脑卒中、痴呆、神经炎症、重金属中毒、神经毒剂中毒。
6.根据权利要求5 所述的应用,其特征为所述脑卒中为缺血性脑卒中或出血性脑卒中。
7.一种药物组合物,其特征在于:含有权利要求1中所述的化合物以及药效学上可接受的载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810808497.8A CN108997451B (zh) | 2018-07-23 | 2018-07-23 | 野八角新倍半萜及其制备方法、应用和药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810808497.8A CN108997451B (zh) | 2018-07-23 | 2018-07-23 | 野八角新倍半萜及其制备方法、应用和药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108997451A CN108997451A (zh) | 2018-12-14 |
CN108997451B true CN108997451B (zh) | 2020-08-11 |
Family
ID=64597029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810808497.8A Expired - Fee Related CN108997451B (zh) | 2018-07-23 | 2018-07-23 | 野八角新倍半萜及其制备方法、应用和药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108997451B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011050481A1 (en) * | 2009-10-30 | 2011-05-05 | National Research Council Of Canada | New eremophilane sesquiterpene lactones from senecio jacobaea |
CN103508988A (zh) * | 2012-06-27 | 2014-01-15 | 南开大学 | 1个新的蜂斗菜内酯(bakkenolide)型的倍半萜的制备及其应用 |
CN106554349A (zh) * | 2016-11-22 | 2017-04-05 | 华北理工大学 | 野八角新异戊烯基取代c6‑c3类化合物及其制备方法、应用和其药物组合物 |
-
2018
- 2018-07-23 CN CN201810808497.8A patent/CN108997451B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011050481A1 (en) * | 2009-10-30 | 2011-05-05 | National Research Council Of Canada | New eremophilane sesquiterpene lactones from senecio jacobaea |
CN103508988A (zh) * | 2012-06-27 | 2014-01-15 | 南开大学 | 1个新的蜂斗菜内酯(bakkenolide)型的倍半萜的制备及其应用 |
CN106554349A (zh) * | 2016-11-22 | 2017-04-05 | 华北理工大学 | 野八角新异戊烯基取代c6‑c3类化合物及其制备方法、应用和其药物组合物 |
Non-Patent Citations (2)
Title |
---|
Sesquiterpenes from the Roots of Illicium jiadifengpi;Guijie Zhang等;《Planta Med》;20131231;第79卷;第1056-1062页 * |
八角属药用植物化学成分研究进展;焦方文 等;《山东中医药大学学报》;20160331;第40卷(第2期);第192-194页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108997451A (zh) | 2018-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180193399A1 (en) | Compound and method for treating spasms, inflammation and pain | |
US20180271924A1 (en) | Compound and method for reducing inflammation, pain, allergy, flu and cold symptoms | |
CN103172643B (zh) | 黄皮咔唑生物碱及其制备方法和其药物组合物与用途 | |
CN109432096B (zh) | 盐酸去亚甲基四氢小檗碱在制备预防或治疗酒精性肝病和非酒精性脂肪肝病药物中的应用 | |
US20050159491A1 (en) | Preparation and application of transhintotalphenolic acid | |
CN107253960B (zh) | 野八角倍半木脂素及其制备方法、应用和药物组合物 | |
CN106432385B (zh) | 一种高纯度灯盏花素提取物及制剂的制备方法及用途 | |
CN107050016A (zh) | 原苏木素a的医药用途 | |
CN107382954A (zh) | 野八角新木脂素及其制备方法、应用和药物组合物 | |
TWI472335B (zh) | 用以治療腸激躁症之山薑屬植物萃取物 | |
CN106831679B (zh) | 新党参炔醇类化合物及其制备方法、应用和其药物组合物 | |
CN106554349B (zh) | 野八角新异戊烯基取代c6-c3类化合物及其制备方法、应用和其药物组合物 | |
CN110452110B (zh) | 一种间苯三酚类天然药物及其制备方法和用途 | |
CN108997451B (zh) | 野八角新倍半萜及其制备方法、应用和药物组合物 | |
CN106543133B (zh) | 野八角新异戊烯基取代c6-c3类化合物及其制备方法、应用和其药物组合物 | |
CN108659089B (zh) | 一种具有抗氧化作用的甾醇化合物及其在制备药物中的应用 | |
CN106800508B (zh) | 野八角中新苯甲酸衍生物及其制备方法、应用和药物组合物 | |
CN111943919B (zh) | 一种间苯三酚类化合物Hyperacmosin C及其制备方法和用途 | |
CN108997468B (zh) | 蒲公英烷型三萜及其制备方法和用途 | |
CN1994277B (zh) | 一种丹参丹酚酸a固体制剂及其制备方法 | |
WO2017124969A1 (zh) | 一种二咖啡酰亚精胺环化衍生物及其用途 | |
CN106749441B (zh) | 党参新炔醇苷类化合物及其制备方法、应用和药物组合物 | |
CN110204477B (zh) | 一种具有抗氧化作用的二萜生物碱及其在制备药物中的应用 | |
CN114394931B (zh) | 具有血管舒张活性的单萜生物碱及其提取方法和应用 | |
CN111718359B (zh) | 一种hyperterpenoid A化合物及其神经保护的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200811 |